#1 Clinical Trials Search in Europe

Transcon Il-2Β/Γ

TransCon IL-2β/γ is an innovative drug being studied in clinical trials for the treatment of various advanced and metastatic solid tumors. This article explores the ongoing research on TransCon IL-2β/γ, its potential benefits, and its role in combination therapies for cancer patients. We’ll discuss the key aspects of these trials, including their objectives, eligibility criteria, and expected outcomes.

Table of Contents

What is TransCon IL-2β/γ?

TransCon IL-2β/γ is a new type of cancer treatment being developed by Ascendis Pharma. It is a modified version of a protein called interleukin-2 (IL-2) that occurs naturally in the body[1]. IL-2 plays an important role in activating the immune system to fight cancer. However, regular IL-2 can cause severe side effects when given as a treatment. TransCon IL-2β/γ is designed to provide the benefits of IL-2 while reducing side effects.

How does it work?

TransCon IL-2β/γ works by stimulating and boosting the immune system to fight cancer cells. Specifically, it activates and increases certain types of immune cells called T cells and natural killer cells that can recognize and attack tumors[1]. The “TransCon” technology allows the IL-2 to be released slowly in the body over time, which may help improve its effectiveness and reduce side effects compared to regular IL-2 treatment.

What cancers can it treat?

TransCon IL-2β/γ is being studied for the treatment of several types of advanced or metastatic solid tumors (cancers that form solid masses). These include[2]:

  • Melanoma (a type of skin cancer)
  • Non-small cell lung cancer
  • Small cell lung cancer
  • Ovarian cancer
  • Cervical cancer
  • Breast cancer (specifically HER2-positive breast cancer)

It is being tested both alone and in combination with other cancer treatments like chemotherapy and immunotherapy drugs.

Clinical trials

TransCon IL-2β/γ is currently being studied in clinical trials to determine if it is safe and effective for treating cancer in humans. Two main clinical trials are ongoing:

1. The BelieveIT-201 trial is testing TransCon IL-2β/γ in combination with other treatments for patients with advanced head and neck cancer[1]. This trial is comparing different treatment combinations to see which works best.

2. The IL Believe trial is a larger study looking at TransCon IL-2β/γ alone and combined with various other treatments for patients with different types of advanced solid tumors[2]. This trial has multiple parts to test the drug’s safety and effectiveness in different situations.

Potential benefits

Some potential benefits being investigated for TransCon IL-2β/γ include:

  • Activating the immune system to fight cancer more effectively
  • Possibly improving response rates to treatment compared to existing therapies
  • Potentially helping patients whose cancer has stopped responding to other immunotherapy drugs
  • Reducing tumor size before surgery in some cancers
  • Possibly extending survival time for patients with advanced cancers

However, it’s important to note that these potential benefits are still being studied and have not yet been proven in large clinical trials[2].

Side effects and safety

As TransCon IL-2β/γ is still in clinical trials, all of its possible side effects are not yet known. The main goal of current studies is to evaluate its safety and determine the right dose to use[2]. Some potential side effects being monitored include:

  • Immune system reactions
  • Fatigue
  • Fever
  • Nausea
  • Changes in blood cell counts

Patients in clinical trials are closely monitored for any adverse reactions. The researchers are working to find the best dose that provides cancer-fighting benefits while minimizing side effects.

Future outlook

TransCon IL-2β/γ is still in the early stages of development, but it shows promise as a potential new treatment option for patients with advanced cancers. If current clinical trials show positive results, larger studies will be needed before it could potentially become available as an approved treatment[2].

Researchers hope that by modifying IL-2, they can harness its cancer-fighting abilities while making it safer and more effective for patients. However, more research is needed to fully understand the benefits and risks of this new therapy.

Aspect Details
Drug Name TransCon IL-2β/γ
Administration Intravenous infusion
Cancer Types Studied Head and neck squamous cell carcinoma, melanoma, breast cancer, cervical cancer, ovarian cancer, non-small cell lung cancer, small cell lung cancer
Trial Phases Phase 1/2
Main Objectives Evaluate safety, tolerability, determine optimal dosage, assess effectiveness
Combination Therapies Pembrolizumab, TransCon TLR7/8 Agonist, standard of care chemotherapy
Key Endpoints Adverse events, objective response rate, progression-free survival, overall survival, pathological complete response
Eligibility Adults with advanced or metastatic solid tumors, specific criteria vary by trial

FAQ

  • What is TransCon IL-2β/γ? TransCon IL-2β/γ is an experimental drug being studied for the treatment of advanced and metastatic solid tumors. It is a modified version of interleukin-2 (IL-2), a protein that helps stimulate the immune system to fight cancer cells.
  • What types of cancer are being studied with TransCon IL-2β/γ? Clinical trials are investigating TransCon IL-2β/γ for various cancer types, including head and neck squamous cell carcinoma, melanoma, breast cancer, cervical cancer, ovarian cancer, non-small cell lung cancer, and small cell lung cancer.
  • How is TransCon IL-2β/γ administered? TransCon IL-2β/γ is administered through intravenous infusion, which means it is delivered directly into the bloodstream through a vein.
  • What are the main objectives of the clinical trials involving TransCon IL-2β/γ? The main objectives include evaluating the safety and tolerability of TransCon IL-2β/γ alone or in combination with other treatments, determining the appropriate dosage, and assessing its effectiveness in fighting cancer by measuring tumor response and survival rates.
  • Who is eligible to participate in these clinical trials? Eligibility varies depending on the specific trial, but generally includes adults with advanced or metastatic solid tumors who have tried other treatments. Participants must meet certain health criteria and have measurable disease. Some trials focus on specific cancer types or stages.

Ongoing Clinical Trials on Transcon Il-2Β/Γ

  • Study of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and Pembrolizumab for Patients with Advanced Head and Neck Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Hungary Italy Poland Spain

  • Study on the Safety and Tolerability of TransCon IL-2 β/γ, Pembrolizumab, and Chemotherapy in Adults with Advanced or Metastatic Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Italy Poland Spain

Glossary

  • TransCon IL-2β/γ: An experimental drug that is a modified version of interleukin-2, designed to stimulate the immune system to fight cancer cells.
  • Neoadjuvant therapy: Treatment given before the main treatment, usually to shrink a tumor before surgery.
  • Metastatic: Cancer that has spread from its original location to other parts of the body.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Pathological complete response (pCR): The absence of all detectable cancer in tissue samples after treatment.
  • Major pathological response (MPR): A significant reduction in cancer cells in tissue samples after treatment, typically defined as ≤10% of cancer cells remaining.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the cancer getting worse.
  • Overall survival (OS): The length of time from the start of treatment that patients are still alive.
  • Adverse events: Unexpected medical problems that happen during treatment with a drug or other therapy.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.

References

  1. http://clinicaltrials.eu/trial/study-of-transcon-tlr7-8-agonist-transcon-il-2-%ce%b2-%ce%b3-and-pembrolizumab-for-patients-with-advanced-head-and-neck-cancer/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-transcon-il-2-%ce%b2-%ce%b3-pembrolizumab-and-chemotherapy-in-adults-with-advanced-or-metastatic-solid-tumors/